Clarix Flo

Phase 3Small molecule

DDavid Sheyn

Clarix Flo is one of 17 small molecule programs targeting Interstitial Cystitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisRecruiting

Interstitial CystitisPhase 3

Recruiting

Competition

Competitive Landscape

16 competitors in Interstitial Cystitis

#DrugCompanyPhaseTrials

Toradol

Roche

Approved

1 2

Elavil

Revia

Cellcept

Pitocin

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 7

Neurontin

VViatris Specialty LLC

Approved

—8

Kenalog

BBausch Health Americas, Inc.

Elmiron

1 10

Neovasculgen

AArtgen Biotech

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Interstitial Cystitis

NCT06096597

Clinical

Trials by Indication[1]

Interstitial Cystitis1 trial

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-Blind, Randomized Controlled Trial

Recruiting·DDavid Sheyn·Preclinical·NCT06096597·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Clarix Flo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clarix Flo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clarix Flo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — David Sheyn company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDavid Sheyn

Clarix Flo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Interstitial Cystitis1 trial

References

Drug Info

Quick Facts

Related News